STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
Market Cap & Net Worth: STRATEC Biomedical AG (SRBZF)
STRATEC Biomedical AG (PINK:SRBZF) has a market capitalization of $657.84K ($657.84K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #36901 globally and #12003 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying STRATEC Biomedical AG's stock price $72.96 by its total outstanding shares 9017 (9.02K).
STRATEC Biomedical AG Market Cap History: 2015 to 2025
STRATEC Biomedical AG's market capitalization history from 2015 to 2025. Data shows growth from $419.40K to $657.84K (4.87% CAGR).
STRATEC Biomedical AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how STRATEC Biomedical AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
STRATEC Biomedical AG's market cap is 0.00 times its annual revenue
0.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.05x
STRATEC Biomedical AG's market cap is 0.05 times its annual earnings
0.00x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $419.40K | $146.89 Million | $22.08 Million | 0.00x | 0.02x |
| 2016 | $425.44K | $184.91 Million | $19.50 Million | 0.00x | 0.02x |
| 2017 | $431.72K | $209.76 Million | $25.64 Million | 0.00x | 0.02x |
| 2020 | $627.96K | $250.10 Million | $25.18 Million | 0.00x | 0.02x |
| 2021 | $635.81K | $287.33 Million | $39.96 Million | 0.00x | 0.02x |
| 2022 | $644.20K | $274.62 Million | $29.22 Million | 0.00x | 0.02x |
| 2023 | $652.88K | $261.91 Million | $13.07 Million | 0.00x | 0.05x |
Competitor Companies of SRBZF by Market Capitalization
Companies near STRATEC Biomedical AG in the global market cap rankings as of March 19, 2026.
Key companies related to STRATEC Biomedical AG by market ranking:
- BERKSHIRE HATH-A (BE:BRH): Ranked #2328 globally with a market cap of $6.43 Billion USD ( €6.27 Billion EUR).
- BERKSHIRE HATH-A - Dusseldorf Stock Exchang (DU:BRH): Ranked #2395 globally with a market cap of $6.17 Billion USD ( €6.02 Billion EUR).
- Itissalat Al-Maghrib (IAM) S.A (PINK:MAOTF): Ranked #3760 globally with a market cap of $3.25 Billion USD.
- NET ONE SYSTEMS (MU:NOX): Ranked #4660 globally with a market cap of $2.24 Billion USD ( €2.18 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #2328 | BERKSHIRE HATH-A | BE:BRH | $6.43 Billion | €634500.00 |
| #2395 | BERKSHIRE HATH-A - Dusseldorf Stock Exchang | DU:BRH | $6.17 Billion | €638000.00 |
| #3760 | Itissalat Al-Maghrib (IAM) S.A | PINK:MAOTF | $3.25 Billion | $14.80 |
| #4660 | NET ONE SYSTEMS | MU:NOX | $2.24 Billion | €1000000.00 |
STRATEC Biomedical AG Historical Marketcap From 2015 to 2025
Between 2015 and today, STRATEC Biomedical AG's market cap moved from $419.40K to $ 657.84K, with a yearly change of 4.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $657.84K | 0.00% |
| 2024 | $657.84K | +0.76% |
| 2023 | $652.88K | +1.35% |
| 2022 | $644.20K | +1.32% |
| 2021 | $635.81K | +1.25% |
| 2020 | $627.96K | +1.32% |
| 2019 | $619.76K | +2.42% |
| 2018 | $605.12K | +40.16% |
| 2017 | $431.72K | +1.48% |
| 2016 | $425.44K | +1.44% |
| 2015 | $419.40K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of STRATEC Biomedical AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $657.84K USD |
| MoneyControl | $657.84K USD |
| MarketWatch | $657.84K USD |
| marketcap.company | $657.84K USD |
| Reuters | $657.84K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.